Cell Signaling Technology

Product Pathways - Growth Factors/Cytokines

Human Erythropoietin (hEPO) #6980

Request pricing for multi-milligram amounts.

Source

Recombinant human Erythropoietin (hEPO) Ala28-Arg193 (Accession #NP_000790) was expressed in human 293 cells at Cell Signaling Technology.

Molecular Characterization

Recombinant hEPO contains no "tags" and the nonglycosylated protein has a calculated MW of 20,417. DTT-reduced and non-reduced protein migrate as 34-40 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation. The expected amino-terminal APPRL of recombinant hEPO was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hEPO. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant hEPO was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 50-400 pg/ml.

Coomassie Gel

Coomassie Gel

The purity of recombinant hEPO was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hEPO and staining overnight with Coomassie Blue.

Bioactivity

Bioactivity

The proliferation of TF-1 cells treated with increasing concentrations of hEPO was assessed. After 48 hour treatment with hEPO, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.

Endotoxin

Less than 0.01 ng endotoxin/1μg hEPO.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hEPO. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

Background

EPO is a 34 kDa protein that is required for the survival and terminal differentiation of erythrocytes (1). EPO is produced by a number of cell types including tubular endothelial cells, interstitial cells, hepatocytes, Kupffer cells, astrocytes, and Schwann cells (2-4). EPO inhibits apoptosis and may protect neuronal cells from death during ischemia and/or neurodegenerative diseases (3,4). EPO inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling (5). EPO protected against the development of diabetes in an animal model by promoting pancreatic β cell survival and growth (6). Binding of EPO to its cognate receptor, EPOR, induces activation of Jak2, Stat5 and Akt (3-5).

  1. Wu, H. et al. (1995) Cell 83, 59-67.
  2. Koury, S.T. et al. (1989) Blood 74, 645-51.
  3. Keswani, S.C. et al. (2011) Proc Natl Acad Sci U S A 108, 4986-90.
  4. Um, M. and Lodish, H.F. (2006) J Biol Chem 281, 5648-56.
  5. Nairz, M. et al. (2011) Immunity 34, 61-74.
  6. Choi, D. et al. (2010) J Exp Med 207, 2831-42.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products